{
  "id": "cluster_0_doc2",
  "content": "Internal memo from Polk Health Network dated 12/01/2023 outlines new coverage exemptions for patients enrolled in the Advanced Gene Therapy Outcomes Study (AGTO-2217). Patients with dual neuropathy/immunodeficiency diagnoses are prioritized for expedited review. Refer to policy exception codes 4400-4500 series. Contact lead coordinator Margo Vescovi at m.vescovi@polkhealth.org for approvals.",
  "metadata": {
    "format": "insurance_memo"
  }
}